Browse Category

Mergers & Acquisitions 3 October 2025 - 15 October 2025

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Hillenbrand announced on Oct. 15 that it will be acquired by Lone Star Funds in an all-cash deal at $32.00 per shareir.hillenbrand.com. At this price, the transaction’s enterprise value is roughly $3.8 billion, including Hillenbrand’s debt. The board said it reviewed multiple strategic options and unanimously determined the offer “is in the best interest of Hillenbrand and its shareholders”ir.hillenbrand.com. Lone Star’s offer represents a 37% premium to Hillenbrand’s pre-deal share price on Aug. 12ir.hillenbrand.com, and 53% above the 90-day average price up to that date. The companies expect the deal to close by the end of Q1 2026, pending Hillenbrand shareholder and regulatory approvalsir.hillenbrand.combenzinga.com. Once completed, Hillenbrand will become privately held and its stock will be delistedir.hillenbrand.combenzinga.com.
15 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

On Oct. 15, Novo Nordisk and Omeros announced a landmark deal licensing zaltenibart, Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not an outright acquisition – and is expected to close in Q4 2025, after which Novo will launch a global Phase 3 trial in PNH and possibly other complement disordersts2.techreuters.com.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk.
15 October 2025
···
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

HOND stock has surged into the mid-$20s after trading in the high teens last week Investing Marketbeat. Its volume spiked and the stock gapped up from $18.86 to $21.69 at open on Oct. 13 Marketbeat. – The catalyst is a proposed merger with Terrestrial Energy Inc., a next-gen nuclear reactor company. The SEC declared the merger’s S-4 registration effective on Sept. 26, and HCM II shareholders will vote on Oct. 20 to approve the deal Businesswire Businesswire. If approved, the combined firm will list on Nasdaq as “IMSR” and “IMSRW” for its warrants Businesswire. – Terrestrial’s technology – an Integral Molten Salt Reactor – is getting major backing. Terrestrial was selected for the DOE’s Nuclear Fuel Line Pilot Program and even got a safety green light from the U.S. Nuclear Regulatory Commission, marking the first-ever NRC approval of a molten-salt reactor design Globenewswire Globenewswire. – Analysts and funds are mixed. MarketBeat notes Weiss Ratings still calls HOND a sell Marketbeat, while an independent analyst at Seeking Alpha just initiated coverage with a Buy, citing Terrestrial’s regulatory momentum and tech edge Seekingalpha. Institutional investors like JPMorgan are accumulating HOND and hedge funds are raising stakes Marketbeat Marketbeat. – Technical indicators are
15 October 2025
··
Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Urban-gro’s announcement of a planned merger with Flash Sports & Media sent its battered stock soaring on October 14. The company revealed it signed a binding LOI to combine with Flash, a private sports-media firm, in what is effectively a reverse mergertipranks.com. Under the proposal, Flash will be absorbed into new Urban-gro subsidiaries, and Flash’s shareholders will receive new Urban-gro shares equal to 19.99% of UGRO’s pre-merger common stock, plus a new series of preferred shares that convert to common upon shareholder approvalsec.govsec.gov. Once the dust settles, Flash’s owners would end up with roughly 90% of the post-merger companysec.gov.
14 October 2025
···
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share marketscreener.com reuters.com. This values Astria at roughly $920M equity and $700M enterprise stocktitan.net. The Boards of both companies approved the deal, which is expected to close in Q1 2026 stocktitan.net. Astria CEO Jill Milne will join BioCryst’s board post-merger stocktitan.net.
14 October 2025
···
BlackRock Soars: Crypto ETFs, AI Funds and Mega M&A Propel Assets to Record $13.5T

BlackRock Soars: Crypto ETFs, AI Funds and Mega M&A Propel Assets to Record $13.5T

BlackRock’s latest earnings and moves underscore its market heft and broad strategy. CEO Larry Fink observed that “record demand” across the firm’s businesses — from technology-driven funds to private credit and ETFs — powered the quarterreuters.com. In particular, strong flows into lower-cost index and cash products drove the fee bump. An analyst noted that all of BlackRock’s new private-market businesses “made healthy contributions” to Q3 resultsreuters.com, validating BlackRock’s aggressive M&A in 2025. Larry Fink said the unified public-private platform positions BlackRock well for what he expects will be a strong Q4reuters.com.
14 October 2025
···
EasyJet Stock Skyrockets on Takeover Rumours – MSC Denies Interest

EasyJet Stock Skyrockets on Takeover Rumours – MSC Denies Interest

On Oct 14 an Italian newspaper reported that MSC, the world’s largest container-ship operator, is exploring a bid for EasyJet. The report said MSC might team up with an investment fund to buy a stake or even full control of the UK airlineproactiveinvestors.commarketscreener.com. In early London trading EasyJet stock soared on the newsreuters.com. By late morning the jump had eased to mid-single digits, especially after MSC publicly denied the rumours. MSC’s emailed statement – “MSC denies any involvement in this matter” – was picked up by Reuters and dampened some of the rallymarketscreener.comxtb.com. EasyJet did not confirm or deny the report when asked.
14 October 2025
··
PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings Inc. is a diversified holding company that grows by acquisitions. Its profile describes it as managing a portfolio of subsidiaries through strategic deals Reuters. Notably, one subsidiary – NorthStrive Biosciences – is a biopharma/medtech firm developing aesthetic and obesity-related treatments Reuters. The other arms provide R&D and investment vehicles. However, PMGC’s recent focus is industrial: it seeks cash-flow positive U.S.-based manufacturing businesses to bolt onto its platform Sec Tipranks. In Jan 2025 the company sold its former skincare subsidiary and pivoted to this model. PMGC is led by CEO/CFO Graydon Bensler and Executive Chairman Braeden Lichti Reuters. Bensler emphasizes acquiring “high-quality, resilient businesses” with consistent profitability in sectors like aerospace, defense and tech hardware Sec. For example, he said of the AGA Precision acquisition: “It exemplifies our focus on … resilient businesses vital to U.S. manufacturing” Sec.
14 October 2025
··
Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Overview of Strive and Its Role: Strive Asset Management began as an ETF issuer and anti-ESG investment firmetf.comglobenewswire.com. In 2025 it transformed into a dedicated Bitcoin-treasury company. Strive’s business is to raise capital and convert it into Bitcoin holdings. The company uses a “preferred equity only” leverage model to accumulate cryptoglobenewswire.com. By merger and acquisitions, Strive aims to become a large public company that simply hoards Bitcoin. Its own COO calls this building a “scaled, innovative and accretive Bitcoin acquisition platform”globenewswire.com. In practice, Strive is effectively a corporatized Bitcoin ETF: shareholders buy Strive stock to get indirect exposure to Bitcoin’s price and the company’s management of that bitcoin hoard.
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate.
11 October 2025
·····
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonistreuters.com. On October 10, 2025, The Wall Street Journal broke the story that J&J is negotiating a purchase of Protagonist Therapeuticsreuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra since a 2017 collaboration dealreuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early confidence in the programreuters.com.
10 October 2025
···
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ Bms Orbitaltx. This approach could greatly simplify CAR‑T therapy logistics. As BMS noted, it may “offer a reduced treatment burden and improved accessibility” relative to conventional ex vivo CAR‑T, which requires cell collection, manufacturing and intensive preparation Bms.
10 October 2025
·
MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

MEDIROM Healthcare Technologies is a Tokyo‑based provider of holistic health and wellness services. Founded in 2000, it operates 300+ Re.Ra.Ku branded relaxation salons across Japan medirom.co.jp, offering massage, aromatherapy and lifestyle therapy. These salons generate the bulk of revenues ir.medirom.co.jp. In parallel, since 2015 MEDIROM has built a Digital Preventative Healthcare arm. Key elements are: the Lav® on-demand health‐guidance app, and the MOTHER Bracelet®, a battery‑free wearable activity tracker. In 2023 it launched REMONY, a remote health monitoring service bundling the MOTHER Bracelet with corporate wellness programs medirom.co.jp. MEDIROM also mentions a “Luxury Beauty” segment, though disclosures emphasize the Relaxation Salon and digital health businesses. Overall, the model is integrated: salon clients use Lav for health guidance, data from Lavender and bracelets feed into big‑data analytics, and corporate partnerships expand applications. CEO Koji Eguchi notes that combining traditional wellness with tech innovation “shows the continued momentum of our market penetration” as the company commercializes its health-tech products medirom.co.jp.
9 October 2025
·
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reportsts2.techts2.techfiercebiotech.com; MarketBeat and DirectorsTalk analyst surveysmarketbeat.comdirectorstalkinterviews.com; Economic Times deal summaryeconomictimes.indiatimes.comeconomictimes.indiatimes.com; Business Wire legal alertbusinesswire.combusinesswire.com; and TradingView market datamarketbeat.comtradingview.com.
9 October 2025
···
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent trades on the NASDAQ under ticker CFLT. According to the company’s historical price lookup, the stock closed at $21.26 on 6 Oct 2025 and dropped to $20.73 on 7 Octinvestors.confluent.io. Technical analysis from StockInvest.us notes the stock fell 2.49 % on 7 Oct, trading between $20.12 and $21.33, and it has declined in six of the last ten sessionsstockinvest.us. Volume was ~7 M shares, lower than earlier sessions, suggesting reduced riskstockinvest.us.
8 October 2025
··
Fifth Third’s $10.9 B Comerica Takeover Shakes Up Banking – Will Comerica Park Get a New Name?

Fifth Third’s $10.9 B Comerica Takeover Shakes Up Banking – Will Comerica Park Get a New Name?

Fifth Third Bancorp, based in Cincinnati, agreed to acquire Comerica Inc. of Dallas in an all-stock transaction valued at $10.9 billionreuters.com. The merger will form the nation’s ninth-largest bank by assets, a financial giant with approximately $288 billion in total assets and a deep footprint across multiple regionsreuters.comts2.tech. Under the deal terms announced October 6, each Comerica share will be exchanged for 1.8663 shares of Fifth Third stockir.53.com. At Fifth Third’s pre-announcement share price, that equates to $82.88 per Comerica share, representing about a 20% premium over Comerica’s recent average trading priceir.53.comts2.tech.
6 October 2025
··
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

The announcement of Fifth Third Bancorp’s planned acquisition of Comerica sent CMA stock soaring. On 6 October 2025, Comerica’s investor‑relations website showed the stock opening near $81.00 and trading around $79.62–$80.56, up 9–14 % from the previous closeinvestor.comerica.com. MarketWatch reported that CMA shares rallied 15.1 % to $81.20, a three‑year high, while Fifth Third’s shares dipped 0.3 %morningstar.com. The initial spike reflected the generous 20 % premium offered by Fifth Third and expectations that the combined bank would command more market share.
6 October 2025
···
White Mountains Stock Rockets +10% on $1.75B Bamboo Deal – What Investors Need to Know

White Mountains Stock Rockets +10% on $1.75B Bamboo Deal – What Investors Need to Know

White Mountains saw one of its biggest single-day moves in years on Oct. 3, 2025. After closing the prior day near $1,665, WTM stock jumped nearly 11% intraday reuters.com, settling around $1,841 by market close. This surge was driven by the surprise announcement that morning: WTM signed an agreement to sell most of its Bamboo homeowners insurance business to private equity firm CVC reuters.com investing.com. Investors reacted strongly because Bamboo had been a high-growth asset for White Mountains. The new deal values Bamboo at $1.75 billion, far above the ~$300 million WTM paid to acquire it in 2024.
3 October 2025
··
1 … 17 18 19 20
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY ON PULLBACK

Microsoft

NASDAQ: MSFT 94 / 100
#2 BUY

L3Harris Technologies

NYSE: LHX 90 / 100
#3 BUY

Xylem

NYSE: XYL 89 / 100
#4 BUY IN TRANCHES

Lam Research

NASDAQ: LRCX 87 / 100
#5 BUY ON WEAKNESS

GE HealthCare

NASDAQ: GEHC 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.